Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes.

While median SNOT-22 scores numerically improved in both subgroups post mepolizumab therapy, these changes did not reach statistical significance, likely reflecting limited sample size, heterogeneous follow-up timing, and missing data.

also in 111,027 other papers